Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 201

1.

Antiplatelet therapy in cerebrovascular disorders.

Weber R, Brenck J, Diener HC.

Handb Exp Pharmacol. 2012;(210):519-46. doi: 10.1007/978-3-642-29423-5_21. Review.

PMID:
22918745
2.

Combination antiplatelet agents for secondary prevention of ischemic stroke.

Vande Griend JP, Saseen JJ.

Pharmacotherapy. 2008 Oct;28(10):1233-42. doi: 10.1592/phco.28.10.1233. Review.

PMID:
18823219
3.

Antiplatelet therapy for stroke prevention.

Hankey GJ.

Curr Atheroscler Rep. 2007 Oct;9(4):312-8. Review.

PMID:
18173959
4.

Update on clinical trials of antiplatelet therapy for cerebrovascular diseases.

Bhatt DL, Kapadia SR, Yadav JS, Topol EJ.

Cerebrovasc Dis. 2000;10 Suppl 5:34-40. Review.

PMID:
11096181
5.

Newer antiplatelet therapies in stroke prevention.

Davis SM, Donnan GA.

Aust Fam Physician. 2001 Feb;30(2):129-34.

PMID:
11280112
6.

The role of warfarin and aspirin in secondary prevention of stroke.

Elkind MS.

Curr Cardiol Rep. 2004 Mar;6(2):135-42. Review.

PMID:
14759359
8.

Clinical pharmacokinetics of antiplatelet agents used in the secondary prevention of stroke.

Lenz T, Wilson A.

Clin Pharmacokinet. 2003;42(10):909-20. Review.

PMID:
12885264
9.

Antiplatelet agents in stroke prevention: acute and long-term treatment strategies.

Weber R, Weimar C, Diener HC.

Hamostaseologie. 2009 Nov;29(4):326-33.

PMID:
19882077
10.

Antiplatelet agents and randomized trials.

Diener HC.

Rev Neurol Dis. 2007 Fall;4(4):177-83. Review.

PMID:
18195669
11.

Clinical considerations in selecting antiplatelet therapy in cerebrovascular disease.

Harbison JW.

Am J Health Syst Pharm. 1998 Oct 1;55(19 Suppl 1):S17-20. Review.

PMID:
9784798
12.

Antiplatelets in secondary stroke prevention: should clopidogrel be the first choice?

Aw D, Sharma JC.

Postgrad Med J. 2012 Jan;88(1035):34-7. doi: 10.1136/postgradmedj-2011-130100. Epub 2011 Nov 25. Review.

PMID:
22121248
13.
14.

Antiplatelet therapy in the prevention of ischemic vascular events: literature review and evidence-based guidelines for drug selection.

Zusman RM, Chesebro JH, Comerota A, Hartmann JR, Massin EK, Raps E, Wolf PA.

Clin Cardiol. 1999 Sep;22(9):559-73. Review.

15.

Prevention of secondary stroke and transient ischaemic attack with antiplatelet therapy: the role of the primary care physician [corrected].

Kirshner HS.

Int J Clin Pract. 2007 Oct;61(10):1739-48. Review. Erratum in: Int J Clin Pract. 2007 Nov;61(11):1957.

16.

Risk-benefit profile of long-term dual- versus single-antiplatelet therapy among patients with ischemic stroke: a systematic review and meta-analysis.

Lee M, Saver JL, Hong KS, Rao NM, Wu YL, Ovbiagele B.

Ann Intern Med. 2013 Oct 1;159(7):463-70. doi: 10.7326/0003-4819-159-7-201310010-00006. Review.

PMID:
24081287
17.

Antiplatelet therapy in ischemic stroke: variability in clinical trials and its impact on choosing the appropriate therapy.

Biller J.

J Neurol Sci. 2009 Sep 15;284(1-2):1-9. doi: 10.1016/j.jns.2009.04.001. Epub 2009 Apr 19. Review.

PMID:
19380153
18.
19.

Prevention of ischaemic stroke--antiplatelets.

McCabe DJ, Brown MM.

Br Med Bull. 2000;56(2):510-25. Review.

PMID:
11092100
20.

Acute ischemic cerebrovascular events on antiplatelet therapy: what is the optimal prevention strategy?

Milionis H, Michel P.

Curr Pharm Des. 2013;19(21):3788-94. Review.

PMID:
23286434

Supplemental Content

Support Center